Pyridazine derivatives and their use for treating diseases mediated by stearoyl-CoA desaturase (SCD) enzymes

Disclosed are pyridazine derivative compounds of formula (I): wherein x, y, W, V, R2, R3, R4, R5, R6, R6a, R7, R7a, R8, R8a, R9 and R9a are as defined in the specification. Pharmaceutical compositions comprising the compounds of formula (I) are also disclosed. These pyridazine derivatives are suitab...

Full description

Saved in:
Bibliographic Details
Main Authors WINTHER, MICHAEL D, ABREO, MELWYN, GSCHWEND, HEINZ W, CHOWDHURY, SULTAN, HOLLADAY, MARK W, KODUMURU, VISHNUMURTHY, RAINA, VANDNA, ZHANG, ZAIHUI, CHAKKA, NAGASREE, SUN, SENGEN, SVIRIDOV, SERGUEI, HOU, DUANJIE, LIU, SHIFENG, LI, WENBAO, CHAFEEV, MIKHAIL, TU, CHI, FU, JIAN-MIN, KAMBOJ, RAJENDER, SUN, SHAOYI
Format Patent
LanguageEnglish
Published 27.11.2009
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:Disclosed are pyridazine derivative compounds of formula (I): wherein x, y, W, V, R2, R3, R4, R5, R6, R6a, R7, R7a, R8, R8a, R9 and R9a are as defined in the specification. Pharmaceutical compositions comprising the compounds of formula (I) are also disclosed. These pyridazine derivatives are suitable for treating a disease or condition mediated by stearoyl-CoA desaturase (SCD) enzymes such as Type II diabetes, impaired glucose tolerance, insulin resistance, obesity, fatty liver, non-alcoholic steatohepatitis, dyslipidemia and metabolic syndrome and any combination of these diseases or conditions.
Bibliography:Application Number: NZ20040545265